Strait & Sound Wealth Management LLC Has $201,000 Stake in Merck & Co., Inc. $MRK

Strait & Sound Wealth Management LLC decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,538 shares of the company’s stock after selling 140 shares during the quarter. Strait & Sound Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $201,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Little House Capital LLC lifted its holdings in shares of Merck & Co., Inc. by 1.2% in the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after purchasing an additional 308 shares in the last quarter. Semus Wealth Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 8.2% in the 1st quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after purchasing an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC lifted its holdings in shares of Merck & Co., Inc. by 20.4% in the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lifted its holdings in shares of Merck & Co., Inc. by 9.8% in the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after purchasing an additional 79,529 shares in the last quarter. Finally, Diversified Trust Co lifted its holdings in shares of Merck & Co., Inc. by 3.8% in the 2nd quarter. Diversified Trust Co now owns 189,651 shares of the company’s stock worth $15,013,000 after purchasing an additional 6,930 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRK. Morgan Stanley cut their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Wells Fargo & Company cut their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday. Citigroup initiated coverage on Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $87.54 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $84.43 and its two-hundred day simple moving average is $81.56. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $106.49. The stock has a market cap of $218.65 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion for the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.